Company intelligence / Profile preview

Orion Therapeutics

Knoxville, Tennessee, United Statesorionthx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Orion Therapeutics has developed the GENESYS™ LNP delivery platform designed to improve the safety and efficacy of RNA-based medicines. The company’s internal pipeline focuses on preclinical development of therapies targeting vascular and cardiovascular diseases. No clinical data or late-stage programs have been reported as of mid–2025.

Therapeutic areas: OtherCardiovascular
Modalities: siRNA (small interfering RNA)mRNA (messenger RNA)General nucleic acid payloads
Industry: Biotech

Partnerships

Engages in strategic collaborations/partnerships for advancing genetic medicines using its GENESYS™ platform; specific partners not named publicly as of June 2025.

Beyond the preview

Go deeper on Orion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orion Therapeutics.